196 related articles for article (PubMed ID: 26787078)
1. Algenpantucel-L immunotherapy in pancreatic adenocarcinoma.
Coveler AL; Rossi GR; Vahanian NN; Link C; Chiorean EG
Immunotherapy; 2016 Feb; 8(2):117-25. PubMed ID: 26787078
[TBL] [Abstract][Full Text] [Related]
2. Pancreatic cancer: Update on immunotherapies and algenpantucel-L.
McCormick KA; Coveler AL; Rossi GR; Vahanian NN; Link C; Chiorean EG
Hum Vaccin Immunother; 2016 Mar; 12(3):563-75. PubMed ID: 26619245
[TBL] [Abstract][Full Text] [Related]
3. Novel pancreatic cancer vaccines could unleash the army within.
Springett GM
Cancer Control; 2014 Jul; 21(3):242-6. PubMed ID: 24955709
[TBL] [Abstract][Full Text] [Related]
4. Addition of algenpantucel-L immunotherapy to standard adjuvant therapy for pancreatic cancer: a phase 2 study.
Hardacre JM; Mulcahy M; Small W; Talamonti M; Obel J; Krishnamurthi S; Rocha-Lima CS; Safran H; Lenz HJ; Chiorean EG
J Gastrointest Surg; 2013 Jan; 17(1):94-100; discussion p. 100-1. PubMed ID: 23229886
[TBL] [Abstract][Full Text] [Related]
5. Immunotherapy for pancreatic cancer: current concepts.
Kaufman HL; Di Vito J; Hörig H
Hematol Oncol Clin North Am; 2002 Feb; 16(1):159-97, viii. PubMed ID: 12063825
[TBL] [Abstract][Full Text] [Related]
6. Potential targets for pancreatic cancer immunotherapeutics.
Dodson LF; Hawkins WG; Goedegebuure P
Immunotherapy; 2011 Apr; 3(4):517-37. PubMed ID: 21463193
[TBL] [Abstract][Full Text] [Related]
7. Immunologic approaches to the management of pancreatic cancer.
Laheru D; Biedrzycki B; Jaffee EM
Cancer J; 2001; 7(4):324-37. PubMed ID: 11561608
[TBL] [Abstract][Full Text] [Related]
8. In vivo induction of dendritic cell-mediated cytotoxicity against allogeneic pancreatic carcinoma cells.
Stift A; Friedl J; Dubsky P; Bachleitner-Hofmann T; Benkoe T; Brostjan C; Jakesz R; Gnant M
Int J Oncol; 2003 Mar; 22(3):651-6. PubMed ID: 12579320
[TBL] [Abstract][Full Text] [Related]
9. Advances in immunotherapy for pancreatic cancer: 2013.
DeVito NC; Saif MW
JOP; 2013 Jul; 14(4):347-53. PubMed ID: 23846925
[TBL] [Abstract][Full Text] [Related]
10. Immune Therapy in Pancreatic Cancer: Now and the Future?
Zhang Y; Choi M
Rev Recent Clin Trials; 2015; 10(4):317-25. PubMed ID: 26374557
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of established pancreatic cancers following specific active immunotherapy with interleukin-2 gene-transduced tumor cells.
Clary BM; Coveney EC; Philip R; Blazer DG; Morse M; Gilboa E; Lyerly HK
Cancer Gene Ther; 1997; 4(2):97-104. PubMed ID: 9080118
[TBL] [Abstract][Full Text] [Related]
12. Gene-mediated cytotoxic immunotherapy as adjuvant to surgery or chemoradiation for pancreatic adenocarcinoma.
Aguilar LK; Shirley LA; Chung VM; Marsh CL; Walker J; Coyle W; Marx H; Bekaii-Saab T; Lesinski GB; Swanson B; Sanchez D; Manzanera AG; Aguilar-Cordova E; Bloomston M
Cancer Immunol Immunother; 2015 Jun; 64(6):727-36. PubMed ID: 25795132
[TBL] [Abstract][Full Text] [Related]
13. Immunotherapeutic Approaches in Pancreatic Adenocarcinoma: Current Status and Future Perspectives.
Yee NS
Curr Mol Pharmacol; 2016; 9(3):231-241. PubMed ID: 26177643
[TBL] [Abstract][Full Text] [Related]
14. Rational combinations of immunotherapy for pancreatic ductal adenocarcinoma.
Blair AB; Zheng L
Chin Clin Oncol; 2017 Jun; 6(3):31. PubMed ID: 28705008
[TBL] [Abstract][Full Text] [Related]
15. Immune checkpoint and inflammation as therapeutic targets in pancreatic carcinoma.
Kimbara S; Kondo S
World J Gastroenterol; 2016 Sep; 22(33):7440-52. PubMed ID: 27672267
[TBL] [Abstract][Full Text] [Related]
16. Pancreatic cancer immunotherapy using a tumor lysate vaccine, engineered to express α-gal epitopes, targets pancreatic cancer stem cells.
Tanida T; Tanemura M; Miyoshi E; Nagano H; Furukawa K; Nonaka Y; Akita H; Hama N; Wada H; Kawamoto K; Kobayashi S; Eguchi H; Mori M; Doki Y
Int J Oncol; 2015 Jan; 46(1):78-90. PubMed ID: 25354268
[TBL] [Abstract][Full Text] [Related]
17. Immunotherapy synergizes with chemotherapy targeting pancreatic cancer.
Koido S; Homma S; Takahara A; Namiki Y; Komita H; Uchiyama K; Ito M; Gong J; Ohkusa T; Tajiri H
Immunotherapy; 2012 Jan; 4(1):5-7. PubMed ID: 22149993
[No Abstract] [Full Text] [Related]
18. Cellular immunotherapy study of prostate cancer patients and resulting IgG responses to peptide epitopes predicted from prostate tumor-associated autoantigens.
Hemstreet GP; Rossi GR; Pisarev VM; Enke CA; Helfner L; Hauke RJ; Tennant L; Ramsey WJ; Vahanian NN; Link CJ
J Immunother; 2013 Jan; 36(1):57-65. PubMed ID: 23211622
[TBL] [Abstract][Full Text] [Related]
19. A phase I clinical trial of lethally irradiated allogeneic pancreatic tumor cells transfected with the GM-CSF gene for the treatment of pancreatic adenocarcinoma.
Jaffee EM; Abrams R; Cameron J; Donehower R; Duerr M; Gossett J; Greten TF; Grochow L; Hruban R; Kern S; Lillemoe KD; O'Reilly S; Pardoll D; Pitt HA; Sauter P; Weber C; Yeo C
Hum Gene Ther; 1998 Sep; 9(13):1951-71. PubMed ID: 9741433
[No Abstract] [Full Text] [Related]
20. A practical approach to pancreatic cancer immunotherapy using resected tumor lysate vaccines processed to express α-gal epitopes.
Furukawa K; Tanemura M; Miyoshi E; Eguchi H; Nagano H; Matsunami K; Nagaoka S; Yamada D; Asaoka T; Noda T; Wada H; Kawamoto K; Goto K; Taniyama K; Mori M; Doki Y
PLoS One; 2017; 12(10):e0184901. PubMed ID: 29077749
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
